GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Total Current Liabilities

Nektar Therapeutics (Nektar Therapeutics) Total Current Liabilities : $51.27 Mil (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Nektar Therapeutics's total current liabilities for the quarter that ended in Dec. 2023 was $51.27

Nektar Therapeutics Total Current Liabilities Historical Data

The historical data trend for Nektar Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Total Current Liabilities Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 353.89 115.78 85.20 68.20 51.27

Nektar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.20 59.88 50.69 52.11 51.27

Nektar Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Nektar Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=26.457+19.259
+Other Current Liabilities+Current Deferred Liabilities
=5.553+0
=51.27

Nektar Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=26.457+19.259
+Other Current Liabilities+Current Deferred Liabilities
=5.553+0
=51.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Nektar Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics (Nektar Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Total Current Liabilities
Comparable Companies
SGMT KPTI GNLX BCAB SCPH VOR CYDY PRQR TELO BSEM OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
ITH:Germany
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Website
https://www.nektar.com
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Executives
Howard W Robin director, officer: President & CEO
Jonathan Zalevsky officer: Chief R&D Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson officer: SVP & General Counsel 1613 RAY DRIVE, BURLINGAME CA 94010
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner officer: Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen officer: VP & Chief Accounting Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Robert Chess director, officer: Executive Chairman
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie officer: SVP, COO & CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott officer: SVP & Chief Commercial Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer director 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau director 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein officer: Chief Scientific Officer 129 ELSIE STREET, SAN FRANCISCO CA 94110

Nektar Therapeutics (Nektar Therapeutics) Headlines

From GuruFocus

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

By PRNewswire • 09-13-2023

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

By PRNewswire • 10-13-2023

Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets

By PRNewswire PRNewswire • 07-26-2022

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

By PRNewswire • 09-27-2023

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy

By PRNewswire PRNewswire • 11-09-2022

Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)

By Business Wire Business Wire • 02-01-2023

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

By PRNewswire PRNewswire • 12-12-2022

Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

By PRNewswire • 08-07-2023

Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets

By PRNewswire PRNewswire • 10-25-2022

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

By PRNewswire • 08-01-2023